<DOC>
	<DOC>NCT01757470</DOC>
	<brief_summary>Effectiveness of risk minimisation interventions for vandetanib in Canada</brief_summary>
	<brief_title>Vandetanib Risk Minimisation Effectiveness</brief_title>
	<detailed_description>As part of the new drug approval process in Canada, AstraZeneca has committed to Health Canada to conduct a Drug Utilization Study among patients recently treated with CAPRELSA (vandetanib) and a Knowledge and Understanding Survey among the prescribing physicians to determine whether the product monograph, communication plan, and educational material developed by AstraZeneca Canada for vandetanib are adequate to provide knowledge about the potential risks associated with this product, and if other medications taken concomitantly with vandetanib are managed adequately.</detailed_description>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Neuroendocrine</mesh_term>
	<criteria>N/A (all patients taking Caprelsa and all prescribers will be contacted for participation). N/A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>effectiveness of risk mitigation,</keyword>
	<keyword>knowledge and understanding survey,</keyword>
	<keyword>drug utilisation study,</keyword>
	<keyword>post marketing commitments</keyword>
</DOC>